Tiger Brokers

BUZZ-Street View: Medtronic's early-stage product cycle strength evident, analysts say

Reuters
Yesterday
BUZZ-Street View: Medtronic's early-stage product cycle strength evident, analysts say

** Medtronic MDT.N surpassed Wall Street expectations for third-quarter profit and revenue on Tuesday, driven by strong demand for its heart devices but left its forecast for full-year adjusted profit unchanged

** Average rating of 34 analysts is "buy"; median PT is $112.17 - data compiled by LSEG

CORE GROWTH DRIVERS IN PLACE

** Needham ("buy," PT: $120) says MDT is in the early stages of a strong product cycle that should accelerate organic revenue growth, and the improved quarterly performance reinforces this view

** Piper Sandler ("neutral," PT: $105) expects MDT's Electrophysiology portfolio to "continue to grow nicely for a while, as physicians seem to appreciate Affera and Sphere-9 overall"

** TD Cowen ("buy," PT: $119) sees MDT's quarterly performance as continued proof that the company is focusing on its core growth drivers

** Morningstar (fair value: $112) says MDT is in the early stages of developing new markets. Continued adoption should give it a strong competitive position over the coming decade as the first major player in both tibial stimulation and renal denervation

(Reporting by Kanchana Chakravarty in Bengaluru)

((Kanchana.Chakravarty@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10